Administration secures 10 million courses of Pfizer COVID-19 oral antiviral
The federal government will purchase 10 million treatment courses of the COVID-19 oral antiviral Paxlovid from Pfizer if the Food and Drug Administration approves or authorizes the drug for emergency use, the administration announced today. Pfizer has requested an emergency use authorization for the drug, which it says reduced the risk of COVID-19-related hospitalization or death by 89% in a phase 2/3 clinical trial. AHA will provide additional information regarding the drug’s distribution and uses once FDA approval is attained and the Administration shares its plans for allocating the available courses of medication.
Related News Articles
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…